EU Approves Keytruda as First-line Treatment for Certain Colorectal Cancers

EU Approves Keytruda as First-line Treatment for Certain Colorectal Cancers

284644

EU Approves Keytruda as First-line Treatment for Certain Colorectal Cancers

The European Commission has approved Keytruda (pembrolizumab) as a first-line therapy for adults with metastatic colorectal cancer whose tumors have certain genetic features, the company announced. The genetic features, according to a press release, include microsatellite instability-high (MSI-H) and deficient mismatch repair (dMMR), both good indicators that tumor cells have impaired DNA repair. These DNA repair deficiencies contribute to increase the number of mutations found in a tumor, as well as the likelihood of it being seen as…

You must be logged in to read/download the full post.